Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific

European Journal of Nuclear Medicine

Volumn 27, Issue 5, 2000, Pages 566-573

  Taki, Junichi ^a   Nakajima, Kenichi ^a   Hwang, Eui Hyo ^a   Matsunari, Ichiro ^a   Komai, Kiyonobu ^a   Yoshita, Mitsuhiro ^a   Sakajiri, Kenichi ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Metaiodobenzylguanidine; Parkinson's disease; Parkinsonism; Sympathetic nervous function

Indexed keywords

(3 IODOBENZYL)GUANIDINE; IODINE 123;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CARDIOSELECTIVITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; PARKINSON DISEASE; PARKINSONISM; RADIATION DOSE DISTRIBUTION; SYMPATHETIC FUNCTION; WHOLE BODY RADIATION;

EID: 0034020939     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050544     Document Type: Article

References (39)

1. 1. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
2. 2. Nakajo M, Shimabukuro K, Yoshimura H, et al. Iodine-131 metaiodobenzylguanidine intra-and extravesicular accumulation in the rat heart. J Nucl Med 1986; 27: 84-89.
3. 3. Tobes MC, Jaques SJ, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985; 26: 897-907.
4. 4. Taki J, Nakajima K, Bunko H, Simizu M, Muramori A, Hisada K. Whole-body distribution of iodine 123 metaiodobenzylguanidine in hypertrophie cardiomyopathy: significance of its washout from the heart. Eur J Nucl Med 1990; 17: 264-268.
5. 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994; 15: 317-323.
6. 6. Matsunari I, Bunko H, Taki J, et al. Regional uptake of iodine-125-metaiodobenzylguanidine in the rat heart. Eur J Nucl Med 1993; 20: 1104-1107.
7. 7. Dae MW, De MT, Botvinick EH, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts - implications for clinical studies. J Nucl Med 1992; 33: 1444-1450.
8. 8. Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med 1993; 34: 57-60.
9. 9. Sisson JC, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
10. 10. Dae MW, Herre JM, O'Connell JW, Botvinick EH, Newman D, Munoz L. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 1991; 17: 1416-1423.
11. 11. Manger WM, Hoffman BB. Heart imaging in the diagnosis of pheochromocytoma and assessment of catecholamine uptake. J Nucl Med 1983; 24: 1194-1196.
12. 12. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas SM, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989; 30: 1182-1191.
13. 13. Sisson JC, Bolgos G, Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J 1991; 121: 1119-1123.
14. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994; 49: 81-84.
15. 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun 1998; 19: 137-142.
16. 123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998; 97: 303-306.
17. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand 1998; 97: 307-314.
18. 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999; 40: 371-375.
19. 19. The Consensus Committee of the American Autonomie Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996; 46: 1470.
20. 20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
21. 21. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
22. 22. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.
23. 23. Taki J, Ichikawa A, Nakajima K, Kawasuji M, Tonami N. Comparison of flow capacities of arterial and venous grafts for coronary artery bypass grafting: evaluation with exercise thallium-201 single-photon emission tomography. Eur J Nucl Med 1997; 24: 1487-1493.
24. 24. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-681.
25. 25. Hughes AJ, Ben SY, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease? A clinicopathologic study. Neurology 1992; 42: 1142-1146.
26. 26. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
27. 27. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26: 171-182.
28. 28. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
29. 29. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 2: 2-7.
30. 131II-meta-iodobenzylguanidine uptake in the isolated rat lung: a potential marker of endothelial cell function. Eur J Nucl Med 1988; 13: 543-547.
31. 131I-metaiodobenzylguanidine in sheep. An in vivo measurement of pulmonary metabolic function. Eur J Nucl Med 1988; 14: 65-70.
32. 131I]iodobenzylguanidine. J Nucl Med 1984; 25: 2-6.
33. 33. Sandler ED, Hattner RS, Parisi MT. Asymmetry of salivary gland I-123 metaiodobenzylguanidine (MIBG) uptake in a patient with cervical neuroblastoma and Horner's syndrome: possible etiologic mechanisms. Pediatr Radiol 1992; 22: 225-226.
34. 34. Nakajo M, Shimabukuro K, Miyaji N, et al. Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma. J Nucl Med 1985; 26: 357-365.
35. 123I-MIBG in patients with phaeochromocytomas and paragangliomas. Nucl Med Commun 1989; 10: 567-576.
36. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1995; 53: 230-234.
37. 37. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
38. 38. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neural Sci 1998; 155: 60-67.
39. 39. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.